Skip to main content
Premium Trial:

Request an Annual Quote

With $1B in the Bank, Invitrogen Hungry for Proteomics, Informatics Acquisitions

SAN FRANCISCO, Jan. 10 - Invitrogen, sitting on $1 billion in cash, is poised to acquire proteomics and informatics companies when it finds the right matches, CEO Lyle Turner said.


Though he would not offer any specific companies, Turner did say the focus was on private "mom and pop" companies.


Turner, speaking at the 20th annual JPMorgan H&Q Healthcare Conference, which ends today, said Invitrogen was evaluating companies for acquisition and licensing deals, though he did not set a specific dollar target for total potential deals in 2002.


The company is interested in proteomics companies with "interesting technology to help scientists label and detect [proteins] more easily," said Turner.


It is also seeking companies with "integrating information technology," he said. Such companies include those with well-annotated genetic information, access to many different databases, and companies with software for performing homology searches.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.